NCT05976321View on ClinicalTrials.gov

A Study of TAK-279 in Adults With or Without Liver Damage

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

TAK-279

TAK-279 capsules.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33146

University of Miami, Miami

78215

American Research Corporation - Texas Liver Institute, San Antonio

78229

Pinnacle Clinical Research - San Antonio, San Antonio

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY